Loading stock data…
ACADIA Pharmaceuticals Inc. (ACAD)
$24.84+0.01 (+0.04%)
Market ClosedLast close Jul 24
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ACADIA Pharmaceuticals Inc. in the Healthcare sector is trading at $24.84 with a market capitalization of $3.7B. Wall Street consensus targets $32.80 (20 analysts), implying a +32.0% move over the next 12 months. The stock is currently 12% below its 52-week high of $28.35, remaining 5.7% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +32.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $268.06M↓ | $283.99M↑ | $278.63M↑ | $264.57M↑ | $244.32M |
| Gross Profit | $243.27M↓ | $257.76M↑ | $256.99M↑ | $243.83M↑ | $223.93M |
| Operating Income | -$4.62M↓ | $17.39M↓ | $35.76M↑ | $32.37M↑ | $19.29M |
| Net Income | $3.64M↓ | $273.57M↑ | $71.78M↑ | $26.67M↑ | $18.99M |
Peer Comparison
JNJUNHPFE
Fundamentals
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agon...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.67B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
9.70
Beta
Defensive asset. Lower volatility than the S&P 500.
0.86
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
30.10%
Volume
Today's trading volume
982,562
Recent News
Wall Street Analysts Believe Acadia (ACAD) Could Rally 30.89%: Here's is How to Trade
The mean of analysts' price targets for Acadia (ACAD) points to a 30.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Acadia Gets FDA's Fast Track Tag for Alzheimer's Disease Candidate
ACAD wins FDA's Fast Track status for remlifanserin in Alzheimer's disease psychosis as its phase II data readout approaches and phase III enrollment advances.
An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors?
Acadia Pharmaceuticals specializes in CNS therapies; a key insider recently trimmed their stake amid ongoing product pipeline developments.
ACADIA Pharmaceuticals (ACAD) Names A New Chief People Officer, Is It Still Below Fair Value?
Acadia Pharmaceuticals (ACAD) has appointed Carl Segerstrom as Chief People Officer. Segerstrom is a human resources veteran with more than 25 years in biopharma leadership and is joining the executive team during an active period for the stock. See our latest analysis for ACADIA Pharmaceuticals. Against this leadership backdrop, ACADIA Pharmaceuticals has seen its share price return rise 23.39% over the past 30 days and 20.61% over 90 days. The 1 year total shareholder return of 24.98%...
Is ACADIA Pharmaceuticals (ACAD) Still Undervalued After The Daybue Win?
ACADIA Pharmaceuticals stock has climbed 20.9% over the past month, and the broad valuation checks currently lean toward the shares looking inexpensive rather than stretched at recent prices. The 20.9% gain over the past month suggests investors have quickly repriced ACADIA Pharmaceuticals, raising the question of how much of the recent optimism is already in the stock. The recent positive opinion from the European Medicines Agency’s CHMP on Daybu for Rett syndrome can support higher growth...